Aptamer Group, the developer of next-generation synthetic binders for the life sciences, entered a new contract valued at up to £617,000 with a top-five pharmaceutical company. The expanded partnership will focus on developing Optimer binders against three therapeutic targets to support drug validation and potential clinical trial applications. The multi-target program follows successful completion of earlier development programs in which Optimer binders demonstrated superior performance char...